142 related articles for article (PubMed ID: 11449334)
1. B-domain deleted recombinant factor VIII formulation and stability.
Osterberg T; Fatouros A; Neidhardt E; Warne N; Mikaelsson M
Semin Hematol; 2001 Apr; 38(2 Suppl 4):40-3. PubMed ID: 11449334
[TBL] [Abstract][Full Text] [Related]
2. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.
Osterberg T; Fatouros A; Mikaelsson M
Pharm Res; 1997 Jul; 14(7):892-8. PubMed ID: 9244146
[TBL] [Abstract][Full Text] [Related]
3. Viral safety of B-domain deleted recombinant factor VIII.
Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
[TBL] [Abstract][Full Text] [Related]
4. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
[TBL] [Abstract][Full Text] [Related]
5. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
Nedergaard H; Vestergaard S; Jensen PT; Kristiansen MW; Jensen MB; Ostergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 Jul; 30(7):1309-15. PubMed ID: 18691990
[TBL] [Abstract][Full Text] [Related]
6. The manufacturing process for B-domain deleted recombinant factor VIII.
Eriksson RK; Fenge C; Lindner-Olsson E; Ljungqvist C; Rosenquist J; Smeds AL; östlin A; Charlebois T; Leonard M; Kelley BD; Ljungqvist A
Semin Hematol; 2001 Apr; 38(2 Suppl 4):24-31. PubMed ID: 11449332
[TBL] [Abstract][Full Text] [Related]
7. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).
Parti R; Schoppmann A; Lee H; Yang L
Haemophilia; 2005 Sep; 11(5):492-6. PubMed ID: 16128893
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional characterization of B-domain deleted recombinant factor VIII.
Sandberg H; Almstedt A; Brandt J; Castro VM; Gray E; Holmquist L; Lewin M; Oswaldsson U; Mikaelsson M; Jankowski MA; Bond M; Scoble HA
Semin Hematol; 2001 Apr; 38(2 Suppl 4):4-12. PubMed ID: 11449330
[TBL] [Abstract][Full Text] [Related]
10. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
[TBL] [Abstract][Full Text] [Related]
11. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
[TBL] [Abstract][Full Text] [Related]
12. Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Nuijen B; Bouma M; Talsma H; Manada C; Jimeno JM; Lopez-Lazaro L; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2001 Sep; 27(8):767-80. PubMed ID: 11699828
[TBL] [Abstract][Full Text] [Related]
13. Second generation, B-domain deleted recombinant factor VIII.
Berntorp E
Thromb Haemost; 1997 Jul; 78(1):256-60. PubMed ID: 9198162
[TBL] [Abstract][Full Text] [Related]
14. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients.
Courter SG; Bedrosian CL
Semin Hematol; 2001 Apr; 38(2 Suppl 4):44-51. PubMed ID: 11449335
[TBL] [Abstract][Full Text] [Related]
16. In vitro stability of recombinant human factor VIII (Recombinate).
Parti R; Ardosa J; Yang L; Mankarious S
Haemophilia; 2000 Sep; 6(5):513-22. PubMed ID: 11012695
[TBL] [Abstract][Full Text] [Related]
17. Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation.
Jameel F; Tchessalov S; Bjornson E; Lu X; Besman M; Pikal M
Pharm Dev Technol; 2009; 14(6):687-97. PubMed ID: 19883259
[TBL] [Abstract][Full Text] [Related]
18. Effect of collapse on the stability of freeze-dried recombinant factor VIII and alpha-amylase.
Wang DQ; Hey JM; Nail SL
J Pharm Sci; 2004 May; 93(5):1253-63. PubMed ID: 15067701
[TBL] [Abstract][Full Text] [Related]
19. Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials.
Hubbard A; Bevan S; Matejtschuk P
Anal Bioanal Chem; 2007 Apr; 387(7):2503-7. PubMed ID: 17072599
[TBL] [Abstract][Full Text] [Related]
20. Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.
D'Amici GM; Timperio AM; Gevi F; Grazzini G; Zolla L
Electrophoresis; 2010 Aug; 31(16):2730-9. PubMed ID: 20737444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
